What is the equivalent bumetanide dose for 240 mg furosemide (frusemide)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Furosemide 240mg to Bumetanide Conversion

For 240 mg furosemide, the equivalent bumetanide dose is 6 mg based on the standard 40:1 conversion ratio.

Conversion Ratio

The established conversion ratio between furosemide and bumetanide is 40:1 1. This means:

  • 1 mg bumetanide = 40 mg furosemide
  • 240 mg furosemide ÷ 40 = 6 mg bumetanide

This 40:1 ratio is consistently cited across multiple guidelines and the FDA drug label 2, 3, 2, 3, 1.

Clinical Context and Dosing Considerations

For intravenous administration in acute heart failure:

  • The ESC guidelines specifically state that furosemide 20-40 mg IV is equivalent to bumetanide 0.5-1 mg 2, 3, 2, 3
  • Maximum recommended daily doses are 240 mg furosemide or 10 mg bumetanide 4, 5
  • Your 240 mg furosemide dose is at the upper limit of recommended 24-hour dosing 2

Route-specific potency differences:

  • Intravenous furosemide is approximately twice as potent as oral furosemide
  • Bumetanide maintains roughly 1:1 oral-to-intravenous equivalence 6
  • When converting from oral furosemide to IV bumetanide, account for this bioavailability difference

Important Caveats

The 40:1 ratio has limitations:

  • Research shows the actual potency ratio varies from 20:1 to 50:1 depending on dose range and patient population 7, 8, 9
  • At higher doses in renal failure, the ratio may approach 20:1 10, 9
  • For natriuresis specifically, the ratio is closer to 46:1 in healthy subjects 9
  • Bumetanide causes less potassium loss per equivalent natriuretic effect 11, 9

Clinical monitoring after conversion:

  • Monitor urine output, daily weights, and renal function closely
  • Bumetanide may produce greater diuresis than expected based on simple ratio conversion 12
  • Risk of electrolyte abnormalities (hyponatremia, hypokalemia) may be higher with bumetanide 12
  • Expect BUN elevation without necessarily indicating true renal dysfunction 12

Dose adjustments in special populations:

  • In chronic renal insufficiency, furosemide may produce superior overall natriuresis despite equal tubular responsiveness 10
  • Consider starting at lower end of conversion (e.g., 5 mg bumetanide for 240 mg furosemide) in renal impairment
  • Neonates and infants require substantially different dosing due to prolonged half-life 13

References

9
Research

Bumetanide and frusemide: a comparison of dose-response curves in healthy men.

British journal of clinical pharmacology, 1978

Related Questions

What is the appropriate IV dose conversion from furosemide (Lasix) to bumetanide (Bumex)?
What is the equivalent intravenous dose of bumetanide (Bumex) for a 40 mg intravenous dose of furosemide (Lasix)?
How to increase diuresis with bumex (bumetanide)?
Is bumetanide more potent than furosemide (Lasix)?
Which loop diuretic—bumetanide (Bumex) or furosemide (Lasix)—is preferred for achieving diuresis in patients with volume overload, considering potency, dosing, renal function, and cost?
Should a patient with a rheumatoid factor of 155 IU/mL be referred to rheumatology?
What laboratory tests should be ordered for the evaluation and management of Kawasaki disease in the emergency department?
What is the significance of a positive antinuclear antibody (ANA) titer of 1:80 with a nuclear dense fine speckled pattern in this patient?
What are the indications for ordering a carcinoembryonic antigen (CEA) test?
What is the appropriate workup for abnormal uterine bleeding in a woman presenting with missed, irregular periods and heavy bleeding?
Provide a SOAP note for a 10‑year‑old female presenting for an annual well‑child visit, first dose of human papillomavirus (HPV) vaccine, Vanderbilt attention‑deficit/hyperactivity disorder (ADHD) assessment due to hyperactivity and difficulty reading and focusing, with a left shoulder drop observed on scoliosis screening, and include appropriate Current Procedural Terminology (CPT) and International Classification of Diseases, Tenth Revision (ICD‑10) codes.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.